Hologic Inc (Hologic) develops, manufactures, and supplies medical imaging systems, diagnostic products and surgical products. It offers products that aid the diagnosis of human diseases; breast imaging and related products and accessories; GYN surgical products, including endometrial ablation system and hysteroscopic tissue removal system; and skeletal health products such as dual-energy X-ray bone densitometry systems and mini C-arm imaging products. The company offers its solutions to surgeons, hospitals, clinical laboratories, and healthcare providers. Hologic offers its products and services through direct sales and a network of independent distributors and sales representatives. The company operates in Europe, the Americas, and Asia-Pacific. Hologic is headquartered in Marlborough, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Hologic Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Hologic Inc Company Overview
- Hologic Inc Company Snapshot
- Hologic Inc Pipeline Products and Ongoing Clinical Trials Overview
- Hologic Inc - Pipeline Analysis Overview
- Business Description
- Hologic Inc - Key Facts
- Hologic Inc - Major Products and Services
- Hologic Inc Pipeline Products by Development Stage
- Hologic Inc Ongoing Clinical Trials by Trial Status
- Hologic Inc Pipeline Products Overview
- Access DXA
- Access DXA Product Overview
- CancerTARGET ID
- CancerTARGET ID Product Overview
- CancerTREATMENT ID
- CancerTREATMENT ID Product Overview
- Dia-CT/NG-050
- Dia-CT/NG-050 Product Overview
- Diagnostic Assay - HBV
- Diagnostic Assay - HBV Product Overview
- Diagnostic Assay - Women's Health
- Diagnostic Assay - Women's Health Product Overview
- GeneSpress
- GeneSpress Product Overview
- LBC Automation Standalone Instrument
- LBC Automation Standalone Instrument Product Overview
- MRSA Nucleic Acid Rapid Test
- MRSA Nucleic Acid Rapid Test Product Overview
- Novodiag Cartridge - Meningitis
- Novodiag Cartridge - Meningitis Product Overview
- Novodiag COVID-19 + InfA/B
- Novodiag COVID-19 + InfA/B Product Overview
- Novodiag System - Bloodstream Infections
- Novodiag System - Bloodstream Infections Product Overview
- Novodiag System - Central Nervous System Infections
- Novodiag System - Central Nervous System Infections Product Overview
- Novodiag System - Respiratory Infections
- Novodiag System - Respiratory Infections Product Overview
- Novodiag System - Sepsis
- Novodiag System - Sepsis Product Overview
- Novodiag System - Skin And Soft Tissue Infections
- Novodiag System - Skin And Soft Tissue Infections Product Overview
- Panther Fusion - Clostridium Difficile Assay
- Panther Fusion - Clostridium Difficile Assay Product Overview
- Panther Fusion - Monkeypox Assay
- Panther Fusion - Monkeypox Assay Product Overview
- Panther Fusion - Mycoplasma Genitalium Resistance Assay
- Panther Fusion - Mycoplasma Genitalium Resistance Assay Product Overview
- Panther Fusion BKV Quant Assay
- Panther Fusion BKV Quant Assay Product Overview
- Panther Fusion EBV Quant Assay
- Panther Fusion EBV Quant Assay Product Overview
- Panther Fusion SARS-CoV-2 Assay
- Panther Fusion SARS-CoV-2 Assay Product Overview
- Panther Fusion SARS-CoV-2 Assay Clinical Trial
- Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
- Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay Product Overview
- Panther System - BKV Assay
- Panther System - BKV Assay Product Overview
- Panther System - Chlamydia Trachomatis Assay
- Panther System - Chlamydia Trachomatis Assay Product Overview
- Panther System - Clostridium Difficile Assay
- Panther System - Clostridium Difficile Assay Product Overview
- Panther System - EBV Assay
- Panther System - EBV Assay Product Overview
- Panther System - Gastrointestinal Infections
- Panther System - Gastrointestinal Infections Product Overview
- Panther System - GBS Assay
- Panther System - GBS Assay Product Overview
- Panther System - Monkeypox Assay
- Panther System - Monkeypox Assay Product Overview
- Panther System - Mycoplasma Genitalium Resistance Assay
- Panther System - Mycoplasma Genitalium Resistance Assay Product Overview
- Panther System - Neisseria Gonorrhoeae Assay
- Panther System - Neisseria Gonorrhoeae Assay Product Overview
- Panther System - SARS-CoV-2/Flu/A/B/RSV Assay
- Panther System - SARS-CoV-2/Flu/A/B/RSV Assay Product Overview
- Panther Trax
- Panther Trax Product Overview
- Quant. fFN Test
- Quant. fFN Test Product Overview
- Second Generation Surgical 5mm Stapler
- Second Generation Surgical 5mm Stapler Product Overview
- Second-Generation Prostate Cancer Assay
- Second-Generation Prostate Cancer Assay Product Overview
- Hologic Inc - Key Competitors
- Hologic Inc - Key Employees
- Hologic Inc - Key Employee Biographies
- Hologic Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Affiliate
- Recent Developments
- Hologic Inc, Recent Developments
- Feb 21, 2023: Hologic “Making a World of Difference” Through Global Sustainability Impact
- Jan 08, 2023: Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023
- Jul 05, 2022: Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022
- Jan 24, 2022: Hologic’s Sustainability Leadership Makes Company “A Global Force for Good”
- Sep 02, 2021: Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
- Jul 28, 2021: Hologic Announces Financial Results for Third Quarter of Fiscal 2021
- Apr 30, 2021: SuperSonic Imagine Announces Q1 2021 Revenues of €6.4 Million, up 31%
- Apr 28, 2021: Hologic Announces Financial Results for Second Quarter of Fiscal 2021
- Feb 10, 2021: Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
- Jan 28, 2021: Hologic expands ultrasound portfolio to address full spectrum of imaging needs
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Hologic Inc Pipeline Products and Ongoing Clinical Trials Overview
- Hologic Inc Pipeline Products by Equipment Type
- Hologic Inc Pipeline Products by Indication
- Hologic Inc Ongoing Clinical Trials by Trial Status
- Hologic Inc, Key Facts
- Hologic Inc, Major Products and Services
- Hologic Inc Number of Pipeline Products by Development Stage
- Hologic Inc Pipeline Products Summary by Development Stage
- Hologic Inc Ongoing Clinical Trials by Trial Status
- Hologic Inc Ongoing Clinical Trials Summary
- Access DXA - Product Status
- Access DXA - Product Description
- CancerTARGET ID - Product Status
- CancerTARGET ID - Product Description
- CancerTREATMENT ID - Product Status
- CancerTREATMENT ID - Product Description
- Dia-CT/NG-050 - Product Status
- Dia-CT/NG-050 - Product Description
- Diagnostic Assay - HBV - Product Status
- Diagnostic Assay - HBV - Product Description
- Diagnostic Assay - Women's Health - Product Status
- Diagnostic Assay - Women's Health - Product Description
- GeneSpress - Product Status
- GeneSpress - Product Description
- LBC Automation Standalone Instrument - Product Status
- LBC Automation Standalone Instrument - Product Description
- MRSA Nucleic Acid Rapid Test - Product Status
- MRSA Nucleic Acid Rapid Test - Product Description
- Novodiag Cartridge - Meningitis - Product Status
- Novodiag Cartridge - Meningitis - Product Description
- Novodiag COVID-19 + InfA/B - Product Status
- Novodiag COVID-19 + InfA/B - Product Description
- Novodiag System - Bloodstream Infections - Product Status
- Novodiag System - Bloodstream Infections - Product Description
- Novodiag System - Central Nervous System Infections - Product Status
- Novodiag System - Central Nervous System Infections - Product Description
- Novodiag System - Respiratory Infections - Product Status
- Novodiag System - Respiratory Infections - Product Description
- Novodiag System - Sepsis - Product Status
- Novodiag System - Sepsis - Product Description
- Novodiag System - Skin And Soft Tissue Infections - Product Status
- Novodiag System - Skin And Soft Tissue Infections - Product Description
- Panther Fusion - Clostridium Difficile Assay - Product Status
- Panther Fusion - Clostridium Difficile Assay - Product Description
- Panther Fusion - Monkeypox Assay - Product Status
- Panther Fusion - Monkeypox Assay - Product Description
- Panther Fusion - Mycoplasma Genitalium Resistance Assay - Product Status
- Panther Fusion - Mycoplasma Genitalium Resistance Assay - Product Description
- Panther Fusion BKV Quant Assay - Product Status
- Panther Fusion BKV Quant Assay - Product Description
- Panther Fusion EBV Quant Assay - Product Status
- Panther Fusion EBV Quant Assay - Product Description
- Panther Fusion SARS-CoV-2 Assay - Product Status
- Panther Fusion SARS-CoV-2 Assay - Product Description
- Panther Fusion SARS-CoV-2 Assay - Clinical Performance Evaluation of the CareSuperb COVID-19 Antigen Home Test
- Panther Fusion SARS-CoV-2 Assay - Study to Compare the Efficacy of ID NOW COVID-19 Assay with Two Lab-based Reference Assays in Nursing Home and Hospitalized Settings Later in Post Symptom Onset
- Panther Fusion SARS-CoV-2/Fl
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton Dickinson and Co
- Boston Scientific Corp
- Carestream Health Inc
- Fujifilm Holdings Corp
- Gynesonics Inc
- IMS Giotto SpA
- Intact Medical Corp
- Koninklijke Philips NV
- MEDIX
- Minerva Surgical Inc
- OrthoScan Inc
- Planmed Oy
- Qiagen NV
- Roche Diagnostics Corp
- Sanarus Technologies LLC
- Siemens AG
- The Cooper Companies Inc
- Toshiba Corp
